Is it possible to identify preclinical signs of systemic lupus erythematosus (SLE) very early and intervene to prevent a patient’s transition to active disease? Who is most at risk to develop lupus among blood relatives of people with the disease, and why?

To answer these questions, researchers study different patient subsets to identify the initial events that occur as at-risk individuals transition to active disease, said Judith A. James, MD, PhD, chair of arthritis and clinical immunology at the Oklahoma Medical Research Foundation, Oklahoma City. Dr. James delivered the 2019 Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lecture, The Winding Road to Lupus at the 2019 ACR/ARP Annual Meeting.

To read the full article please click here.